OPC-184337

OPC-184337 is a small molecule drug candidate being developed by Otsuka Pharmaceutical for the treatment of attention deficit hyperactivity disorder (ADHD). It functions as a dopamine D1 receptor positive allosteric modulator (PAM). By selectively modulating the D1 receptor, OPC-184337 aims to enhance dopaminergic signaling in the prefrontal cortex, a region critical for executive function, attention, and impulse control. This mechanism is hypothesized to provide therapeutic benefits for ADHD symptoms with a potentially improved safety profile compared to traditional stimulants or full D1 agonists. As of 2024, the compound is in Phase 1 clinical development, including single ascending dose studies in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetic properties.